China’s AI Drug-Design Deals Rise Amid US Scrutiny

China’s AI-driven drug firms are expanding globally despite U.S. scrutiny. They secured $93 billion in licensing deals in 2026, a significant rise. Metis TechBio struck a major deal with Boulevard Bio.

Key Points

• Riding a wave of booming cross-border dealmaking, China’s AI-driven drug-design firms are gaining global prominence despite increased U.S. scrutiny. Chinese biotech companies struck out-licensing deals worth $75 billion in early 2026, a significant rise since 2020, according to HSBC.

• In the first five months of 2026, 169 licensing deals were signed, valued at $93 billion, marking an 87% increase from the previous year. Metis TechBio’s agreement with Boulevard Bio exemplifies this trend, involving upfront payments and potential milestone earnings.

• Meanwhile, the U.S. has added Alibaba, BYD, Baidu, and other Chinese tech giants to its military blacklist amid these developments.

Amid a surge in cross-border transactions, China’s AI-driven drug-design firms are making significant global strides, despite increased U.S. scrutiny of Chinese biotech companies. The out-licensing deals between Chinese biotech firms and major multinational pharmaceutical companies have soared, reaching a value of $75 billion within the first five months of 2026, a substantial increase from virtually none before 2020. This burgeoning activity has culminated in 169 licensing deals, accumulating to $93 billion—an 87% increase from the previous year—demonstrating China’s robust entry into the global pharmaceutical market.

A notable development occurred with Metis TechBio, a prominent AI-driven drug-design company operating in both China and the United States. Following its debut on the Hong Kong stock market, Metis TechBio secured a significant cross-border agreement with Boulevard Bio, a biotechnology firm supported by New York investment firm Deerfield Management. Under this agreement, Metis TechBio is set to receive an upfront payment of $20 million and could potentially earn up to $1.6 billion in milestone payments, along with tiered royalties on future product sales. In exchange, Boulevard Bio acquired the global rights to develop, manufacture, and commercialize MTS-128, Metis TechBio’s advanced AI-powered cancer treatment candidate.

These collaborative ventures signify a pivotal moment for Chinese biotech companies, showcasing their capability to attract substantial international partnerships and funding, further cementing China’s burgeoning influence in the global biotech industry.

Source link : China AI drug-design deals swell as US scrutiny mounts